Deals this week: HitGen, Calithera Biosciences, Esperion Therapeutics
Chinese-biotech company HitGen has signed an agreement with Danish pharmaceutical company LEO Pharma to use its advanced technology platform to discover new small molecules.
The molecules will be licensed to LEO Pharma and used for multiple therapeutic targets. HitGen will receive an initial upfront payment as well as milestone-based payments from LEO Pharma.
US-based pharmaceutical company Calithera Biosciences plans to raise gross proceeds of $250m through an offering of shares of its common stock.
Calithera plans to use the funds towards working capital and general corporate purposes.
Esperion Therapeutics plans for a public offering of common stock shares to raise up to $150m.
The US-based pharmaceutical company plans to use the funds to progress its CLEAR Outcomes CVOT clinical trials.
US-based biopharmaceutical company Dynavax Technologies plans for a public offering of shares of its common stock to raise up to $125m.
The company plans to use the funds towards the commercial launch of HEPLISAV-B.